Home > Annual Financials > KREBS BIOCHEMICALS & INDUSTRIES

KREBS BIOCHEMICALS & INDUSTRIES Financial Statement Analysis
[BOM: 524518|NSE : KREBSBIO]

The Revenues of KREBS BIOCHEMICALS & INDUSTRIES have decreased by -3.28% YoY .
The Earnings Per Share (EPS) of KREBS BIOCHEMICALS & INDUSTRIES has decreased by Negative YoY.
AD     Remove this Ad

KREBS BIOCHEMICALS & INDUSTRIES Last 5 Annual Financial Results
[BOM: 524518|NSE : KREBSBIO]

StandaloneMar2025
Mar2024
Mar2023
Mar2022
Mar2021
Revenues ₹50 Cr₹52 Cr₹60 Cr₹54 Cr₹33 Cr
Expenses ₹59 Cr₹68 Cr₹94 Cr₹71 Cr₹52 Cr
Operating Profit (Excl OI) ₹-8.72 Cr₹-16 Cr₹-34 Cr₹-18 Cr₹-19 Cr
Other Income ₹0.45 Cr₹0.62 Cr₹1.16 Cr₹0.62 Cr₹0.37 Cr
Interest ₹4.69 Cr₹2.97 Cr₹5.39 Cr₹6.28 Cr₹6.00 Cr
Depreciation ₹6.77 Cr₹6.56 Cr₹6.30 Cr₹5.12 Cr₹4.68 Cr
Profit Before Tax ₹-20 Cr₹-25 Cr₹-45 Cr₹-28 Cr₹-29 Cr
Profit After Tax ₹-20 Cr₹-25 Cr₹-45 Cr₹-28 Cr₹-29 Cr
Earnings Per Share (Rs)₹-12.49₹-9.15₹-11.45₹-20.65₹-14.45
PAT Margin (%)-62.20-39.13-47.36-74.58-52.81
ROE(%)0.000.000.000.000.00
ROCE(%)-29.92-18.99-28.59-57.38-40.28
Total Debt/Equity(x)-1.45-1.62-1.84-1.91-2.37

Key Financials

Market Cap : ₹ 125.3 Cr
Revenue (TTM) : ₹ 27.2 Cr
Net Profit(TTM) : ₹ -27.5 Cr
EPS (TTM) : ₹ -12.7
P/E (TTM) : -

Industry Peers & Returns1W1M1Y
KREBS BIOCHEMICALS & INDUSTRIES 0.6% -14.7% -47.7%
SUN PHARMACEUTICAL INDUSTRIES 7.1% -1.5% -6.2%
DIVIS LABORATORIES 2.8% -2.8% 6%
CIPLA 0.2% -12.5% -7.9%
TORRENT PHARMACEUTICALS 3.1% 4.2% 18.8%
DR REDDYS LABORATORIES 2.2% -1.6% 0%
MANKIND PHARMA 2.6% -2.1% -16.6%
ZYDUS LIFESCIENCES 1.4% -1.5% -5.7%
LUPIN 2.6% 3.8% 2.9%


KREBS BIOCHEMICALS & INDUSTRIES Revenues
[BOM: 524518|NSE : KREBSBIO]

Y-o-Y

-3.28 %

5 Yr CAGR

10.84 %

Years Revenues % Change
Mar2025 ₹50 Cr
-3.28
Mar2024 ₹52 Cr
-12.68
Mar2023 ₹60 Cr
11.18
Mar2022 ₹54 Cr
60.72
Mar2021 ₹33 Cr -


KREBS BIOCHEMICALS & INDUSTRIES Operating Profit
[BOM: 524518|NSE : KREBSBIO]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years Operating Profit % Change
Mar2025 ₹-8.72 Cr
Negative
Mar2024 ₹-16 Cr
Negative
Mar2023 ₹-34 Cr
Negative
Mar2022 ₹-18 Cr
Negative
Mar2021 ₹-19 Cr -

Operating Margins
Y-o-Y

Negative

5 Yr CAGR

Negative

Years Operating Margin% % Change
Mar2025 -17.3%
Negative
Mar2024 -30.27%
Negative
Mar2023 -56.94%
Negative
Mar2022 -32.73%
Negative
Mar2021 -55.53% -

KREBS BIOCHEMICALS & INDUSTRIES Profit After Tax
[BOM: 524518|NSE : KREBSBIO]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years Profit After Tax % Change
Mar2025 ₹-20 Cr
Negative
Mar2024 ₹-25 Cr
Negative
Mar2023 ₹-45 Cr
Negative
Mar2022 ₹-28 Cr
Negative
Mar2021 ₹-29 Cr -

PAT Margins
Y-o-Y

Negative

5 Yr CAGR

Negative

Years PAT Margin(%) % Change
Mar2025 -62.2 %
Negative
Mar2024 -39.13 %
Negative
Mar2023 -47.36 %
Negative
Mar2022 -74.58 %
Negative
Mar2021 -52.81 % -

KREBS BIOCHEMICALS & INDUSTRIES Earnings Per Share (EPS)
[BOM: 524518|NSE : KREBSBIO]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years EPS % Change
Mar2025 ₹-12
Negative
Mar2024 ₹-9.15
Negative
Mar2023 ₹-11
Negative
Mar2022 ₹-21
Negative
Mar2021 ₹-14 -

KREBS BIOCHEMICALS & INDUSTRIES Return on Capital Employed (ROCE)
[BOM: 524518|NSE : KREBSBIO]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years ROCE % Change
Mar2025 -29.92%
Negative
Mar2024 -18.99%
Negative
Mar2023 -28.59%
Negative
Mar2022 -57.38%
Negative
Mar2021 -40.28% -

KREBS BIOCHEMICALS & INDUSTRIES Share Price vs Sensex

Current Share Price : ₹58.0
Current MarketCap: ₹ 125.3 Cr
Updated EOD on :Feb 02,2026

Share Price Returns(%) 1 Week 1 Month 1 Year
KREBS BIOCHEMICALS & INDUSTRIES

0.6%

-14.7%

-47.7%

SENSEX

1.7%

-1.7%

10.3%

KREBS BIOCHEMICALS & INDUSTRIES related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about KREBS BIOCHEMICALS & INDUSTRIES Financials


How the annual revenues of KREBS BIOCHEMICALS & INDUSTRIES have changed ?

The Revenues of KREBS BIOCHEMICALS & INDUSTRIES have decreased by -3.28% YoY .

How the Earnings per Share (EPS) of KREBS BIOCHEMICALS & INDUSTRIES have changed?

The Earnings Per Share (EPS) of KREBS BIOCHEMICALS & INDUSTRIES has decreased by Negative YoY .